Lantern Pharma announced its management team will present at the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental in New York. The presentation will focus on the company's progress in using artificial intelligence to transform oncology drug discovery and development. This approach represents a fundamental shift in how cancer therapies are discovered and developed, potentially reducing both the time and cost traditionally associated with bringing new oncology treatments to market.
The company's proprietary AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and utilizes more than 200 advanced ML algorithms to address significant challenges in cancer drug development. Lantern Pharma's growing pipeline includes multiple development programs spanning various cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company currently has a Phase 2 clinical program and multiple Phase 1 clinical trials underway. The full scope of the company's development activities and platform capabilities can be reviewed in their corporate newsroom at https://ibn.fm/LTRN.
The potential market impact of Lantern Pharma's AI-driven pipeline is substantial, with estimated combined annual market potential exceeding $15 billion. More importantly, the company's approach could provide life-changing therapies to hundreds of thousands of cancer patients worldwide by accelerating the development of targeted treatments. The company's presentation at the ThinkEquity Conference will provide investors and industry observers with insights into how artificial intelligence is reshaping cancer drug development and creating new opportunities for addressing unmet medical needs in oncology.
Additional details about the conference presentation and the company's broader strategic initiatives are available through the official press release at https://ibn.fm/QSF41. The conference presentation represents an important opportunity for the company to demonstrate how its AI platform is advancing multiple therapeutic candidates through clinical development while potentially setting new standards for efficiency in oncology research. This development matters because it showcases how technology is fundamentally changing pharmaceutical development, potentially bringing effective cancer treatments to patients faster and more efficiently than traditional methods allow.
